about
The P 2 ′ residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activityA functional and structural study of the major metalloprotease secreted by the pathogenic fungus Aspergillus fumigatusDual-functional, receptor-targeted fluorogenic probe for in vivo imaging of extracellular protease expressionsPathway-selective antagonism of proteinase activated receptor 2.CLCAs - a family of metalloproteases of intriguing phylogenetic distribution and with cases of substituted catalytic sites.Bradykinin release avoids high molecular weight kininogen endocytosis.Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.Comprehensive RNA-Seq Profiling to Evaluate the Sheep Mammary Gland Transcriptome in Response to Experimental Mycoplasma agalactiae Infection.Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancerMultiplex imaging of an intracellular proteolytic cascade by using a broad-spectrum nanoquencher.A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice.Cystatin superfamily.Protease sensing with nanoparticle based platforms.The Use of Antibodies in Small-Molecule Drug Discovery.Inhibitory effect of FSLLRY-NH2 on inflammatory responses induced by hydrogen peroxide in HepG2 cells.Rational design and synthesis of affinity matrices based on proteases immobilized onto cellulose membranes.Oxidative stress induced mechanisms in the progression of periodontal diseases and cancer: a common approach to redox homeostasis?Polymorphism L26V in the cathepsin B gene may be associated with a risk of prostate cancer and differentiation.Development of a periplasmic FRET screening method for protease inhibitory antibodies.Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.Orphan neuropeptides and receptors: Novel therapeutic targets.Site-specific conjugation of the quencher on peptide's N-terminal for the synthesis of a targeted non-spreading activatable optical probe.Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.A lysosome-targeted drug delivery system based on sorbitol backbone towards efficient cancer therapy.Selectivity Conversion of Protease Inhibitory Antibodies
P2860
Q27671330-EA81F3D2-A99A-487E-97F5-0AEFF9E9902FQ27686974-4B40B6CE-72B6-46A7-B71F-86E5ADAF8236Q30501344-A6C78CC2-7381-4170-8263-1A763F4C1603Q34571419-0686F5C0-B623-4236-8B46-D0088708AEAEQ34720540-B42594AC-0C65-483A-A8F9-DAB22672E44CQ35589829-A38A0128-3631-4897-B680-3ED8AD9DA861Q35803029-E67B9D2B-54E9-4A02-8528-FB088DDAA603Q36247786-A8FF7135-A587-4C96-BD82-C9D0BA7D4974Q36254477-917C9570-7625-4F98-BF81-74C63120A30FQ36493144-1AF77A41-DA40-4F45-90A4-8D0535516C53Q36755414-13D01A44-16E7-4EDF-A180-FD5430AA5415Q37098934-F798B67F-1535-43E8-A0B9-1CBBB5313C09Q37226344-468FB5C9-E10C-4AB3-8104-8C3CF768CF40Q37696036-16BA59D5-9962-4D24-A5D3-BDBE1592AAA4Q37793922-A0CC8A79-F341-4837-BE20-E57BC3DA45C4Q38201635-946C3C24-C886-42FD-9109-109E30261458Q38712691-E8A14054-8737-4987-918F-307FC93E2AD9Q38840826-A695FF06-7F02-45FB-9252-D3C8A868BF29Q41830016-155A615C-8495-4670-B677-D24A5BB8E67EQ43237424-8D9EA19F-50CE-4428-8B2C-7BCC22FA3C6FQ46033483-5187B6E8-A574-4912-AF90-BE3161264CF4Q47098588-9D706366-1D2D-413F-8B0F-A751E684811AQ47366066-2881D1E0-6CF1-443B-BB5C-338F3BC55E7AQ51711379-DDDBBA72-11B4-4D56-BA57-7404329AEC25Q52657347-EDD8EEAA-0255-48C7-B3A4-8466ADA2B997Q53031862-F9EAECDF-ADA3-4F3B-B2EB-60340D260443Q58556656-29326128-A158-40A2-96ED-CC3348583A73
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Extracellular proteases as targets for drug development
@ast
Extracellular proteases as targets for drug development
@en
type
label
Extracellular proteases as targets for drug development
@ast
Extracellular proteases as targets for drug development
@en
prefLabel
Extracellular proteases as targets for drug development
@ast
Extracellular proteases as targets for drug development
@en
P2860
P1476
Extracellular proteases as targets for drug development
@en
P2093
Gregg B Fields
Mare Cudic
P2860
P304
P356
10.2174/138920309788922207
P577
2009-08-01T00:00:00Z